Tryme-MR Mechanism of Action

Pharmacology: Pharmacodynamics: Mechanism of action: Trimetazidine inhibits β-oxidation of fatty acids by blocking long chain 3-ketoacyl-CoA thiolase, which enhances glucose oxidation. In an ischemic cell, energy obtained during glucose oxidation requires less oxygen consumption than in the β-oxidation process. Potentiation of glucose oxidation optimizes cellular energy processes, thereby maintaining proper energy metabolism during ischaemia.
Pharmacodynamic effects: In patients with ischemic heart disease, trimetazidine acts as a metabolic agent, preserving the myocardial high-energy phosphate intracellular levels. Anti-ischemic effects are achieved without concomitant hemodynamic effects.
Clinical efficacy and safety: Clinical studies have demonstrated the efficacy and safety of trimetazidine in the treatment of patients with chronic angina, either alone or when the benefit from other antianginal medicinal products was insufficient.
Pharmacokinetics: After oral administration, maximum concentration is found on average, 5 hours after taking the tablet. Over 24 hours, the plasma concentration remains at levels >75% of the maximum concentrations for 1 hour. Steady state is reached by the 60th hour, at the latest. Trimetazidine is eliminated primarily in the urine, mainly in the unchanged form.